Esperion (ESPR) announced the appointment of John Harlow as the Company’s Chief Commercial Officer, effective November 17, 2025. Harlow will join Esperion’s Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. He joins Esperion from Melinta Therapeutics where he served as Chief Commercial Officer from early 2021.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- ESPR Earnings this Week: How Will it Perform?
- Esperion’s Strategic Advancements and Growth Potential: Buy Rating Affirmed
- Esperion announces nomination of ESP-2001 as preclinical development candidate
- Esperion Announces Public Offering to Raise $70.2 Million
- Gold tops $4,000, SoftBank buys robotics unit: Morning Buzz